The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study
Heikinheimo, O.; Lehtovirta, P.äi.; Aho, I.; Ristola, M.; Paavonen, J.
American Journal of Obstetrics and Gynecology 204(2): 126.E1-4
2011
ISSN/ISBN: 1097-6868 PMID: 21035781 DOI: 10.1016/j.ajog.2010.09.002Document Number: 217941
We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device. Fifteen women using the LNG-IUS and their 25 age- and CD4(+) lymphocyte count-matched control subjects with annual follow-up data were followed up for 5 years. No unplanned pregnancies or pelvic infections occurred among the LNG-IUS users. Altogether, 12 (80%) of the LNG-IUS users continued its use up to 5 years. Annual CD4(+) lymphocyte counts were similar in the LNG-IUS users and control subjects throughout the follow-up period. The hemoglobin levels increased initially (P < .005) and remained higher among the LNG-IUS users (P < .02). Pap smears displayed non-squamous intraepithelial lesion cytology in ≥ 85% of cases in both groups. No unfavorable effects on the course of HIV infection were noted during long-term use of the LNG-IUS. Dual protection by means of an LNG-IUS and condoms might be an ideal contraceptive strategy for HIV-infected women.
Document emailed within 0-6 h
